NICE first rejected Kadcyla back in 2014, saying its cost of around £91,000 per patient at full price was too high, and that a small discount was not enough for it to be considered cost effective.

The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount ...

Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...

It is essential to understand the 7 different types of logos and when to use them. Each type has strong and weak points - Need professional help? Ever wonder why some logos stick in your mind like ...

What comes to mind when you think about sportswear? Is it the smoothness of running shoes or the convenience of your favourite gym shorts? Or maybe those famous logos let you know at a glance which ...